Semaglutide is a GLP-1 receptor agonist and one of the most clinically established compounds in this category, holding FDA approval under three brand names — Ozempic and Rybelsus for type 2 diabetes, and Wegovy for…
🔬 Studied for: Glycemic-Control Research
💊 Also studied for: Weight-Management Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
Semaglutide is a GLP-1 receptor agonist and one of the most clinically established compounds in this category, holding FDA approval under three brand names — Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management.
Semaglutide mimics the naturally occurring incretin hormone GLP-1, slowing gastric emptying, increasing insulin secretion in response to meals, and acting on appetite-regulating centers in the hypothalamus — mechanisms documented extensively across its clinical trial program.
These are effects Semaglutide has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Semaglutide's original approval was for type 2 diabetes management, supported by a large body of Phase 3 trial data (the SUSTAIN program) demonstrating improved blood glucose control.
Subsequent trials (the STEP program) established Semaglutide's efficacy for chronic weight management at higher doses, leading to its approval as Wegovy and making it one of the most-studied compounds in current obesity pharmacology.
The FDA-approved clinical dosing follows a titration schedule specific to each branded product and indication, detailed in the respective prescribing information for Ozempic, Wegovy, and Rybelsus — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not provide dosing recommendations. Semaglutide is sold for laboratory research use only and is not intended for human consumption.
As an FDA-approved medication, Semaglutide's side-effect profile is well documented in its prescribing information, most commonly gastrointestinal effects (nausea, vomiting, diarrhea, constipation), along with rare but serious risks discussed in its labeling (such as pancreatitis and gallbladder disease). Research-grade material sourced outside the regulated pharmacy supply chain has not undergone the same quality controls and carries additional, unverified risk.
No. Semaglutide is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Glycemic-Control Research — Semaglutide's original approval was for type 2 diabetes management, supported by a large body of Phase 3 trial data (the SUSTAIN program) demonstrating improved blood glucose control.
In the US, UK, Canada and Australia, Semaglutide is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Semaglutide's extensive clinical trial data (SUSTAIN and STEP programs) and prescribing information are available via the FDA and indexed on PubMed under "Semaglutide GLP-1 clinical trial."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.